Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy

Table 3 Postoperative characteristics of 109 ER-positive/HER2-negative breast cancer patients who underwent neoadjuvant chemotherapy

	Number	Percent
Pathologic stage, postoperative^a
yp0 (pathologic CR)	8	7.3
yp1A	21	19.3
yp1B	7	6.4
yp2A	25	22.9
yp2B	20	18.3
yp3A	21	19.3
yp3B	0	0
yp3C	7	6.4
ER, Allred score^b
0–2	13	13.8
3–5	4	4.3
6–8	77	81.9
PR, Allred score^b
0–2	24	25.5
3–5	30	31.9
6–8	40	42.6
Ki67 index status^b, %
< 14	67	71.3
14–100	25	26.6
NE	2	2.1
Lymphovascular invasion^b	37	39.4
Histological grade^b,c
G1	20	18.3
G2	56	51.3
G3	14	12.8
NE	19	17.4
Recurrence	18	16.5
Local	1
Regional	1
Regional ➔ distant	2
Distant	14
Death	12	11.0
breast cancer-related	11	10.1

Abbreviations: CR Complete response, ER Estrogen receptor, PR Progesterone receptor, NE Not evaluated
^aAJCC 8th edition
^bEvaluated among 94 patients who had residual tumors of the operated breast
^cModified Scarff-Bloom-Richardson grading system

ISSN: 1471-2407